Related Experiment Video

Updated: May 13, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

CD154: the atherosclerotic risk factor in rheumatoid arthritis?

Ghada S Hassan, Daniel Yacoub, Nada Alaaeddine

    Arthritis Research & Therapy
    |February 26, 2013
    PubMed

    Insights

    Rheumatoid arthritis (RA) and atherosclerosis share inflammatory pathways, with CD154 signaling potentially linking these conditions. Understanding this connection may reveal new therapeutic targets for cardiovascular complications in RA patients.

    Area of Science:

    • Cardiovascular Medicine
    • Immunology
    • Rheumatology

    Background:

    • Atherosclerosis is a chronic inflammatory arterial disease.
    • Rheumatoid arthritis (RA) is an autoimmune disease with increasing associations with vascular disorders.
    • Shared etiological features, particularly inflammation, link autoimmune and vascular diseases.

    Purpose of the Study:

    • To review the relationship between RA and vascular abnormalities.
    • To explore the role of CD154 as a potential mediator in RA-associated atherosclerosis.
    • To highlight CD154 as a biological link between RA and cardiovascular complications.

    Main Methods:

    • Literature review of studies on RA, atherosclerosis, and inflammation.
    • Analysis of the role of CD154 and its receptors in disease pathogenesis.
    • Synthesis of evidence on shared inflammatory pathways.

    Main Results:

    • Inflammation is a key driver in the pathogenesis of both RA and atherosclerosis.
    • CD154 and its receptors are implicated in the development of RA and atherosclerosis.
    • CD154 signaling triggers inflammatory responses common to both diseases.

    Conclusions:

    • The CD154 axis represents a significant biological link between RA and atherosclerosis.
    • CD154 may be a crucial mediator in the development of atherosclerotic events in RA patients.
    • Targeting CD154 could offer therapeutic strategies for cardiovascular complications in RA.

    More Related Videos

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

    Published on: June 6, 2025

    Quantification of Atherosclerosis in Mice06:59

    Quantification of Atherosclerosis in Mice

    Published on: June 12, 2019

    Related Concept Videos

    Atherosclerosis I: Introduction01:30

    Atherosclerosis I: Introduction

    Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
    Rheumatic Heart Disease I: Introduction01:23

    Rheumatic Heart Disease I: Introduction

    Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

    Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

    Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
    Coronary Artery Disease I: Introduction01:30

    Coronary Artery Disease I: Introduction

    Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
    Inflammation01:38

    Inflammation

    Overview